N-acetylcysteine as a promising treatment for COVID-19: A comprehensive meta-analysis of systemic manifestations and clinical outcomes
Abstract
The COVID-19 pandemic presents systemic disorders, primarily affecting respiratory and cardiovascular systems. N-acetylcysteine (NAC) possesses antioxidative, anti-inflammatory, and immune-modulating properties, suggest-ing a potential therapy against COVID-19. In the current study, a meta-analysis was conducted to investigate the effectiveness of NAC supplementation against COVID-19. A literature search was conducted from April 2019 to December 2023 using Rev-Man 5.3 incorporating 14 studies with 20,980 participants. Results revealed significant differences in total and native thiol, and hydrogen sulfides in COVID-19 patients. NAC-treated patients exhibited significant reduction in C-reactive protein and D-dimer levels, along with higher pO2/FiO2 ratios, minimal stay in hospital, and lower mortalities supporting the efficacy of NAC toward COVID-19. Please see corrigendum at: https://itjfs.com/index.php/ijfs/article/view/3625
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 20,980 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.